COMPANY PROFILE

Biogen

Explore full profile

Innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases

Cambridge, United StatesFounded 1978Biotech & Life Sciences

Valuation $41B Market cap · 2026

Revenue $10B Latest reported FY

EBITDA $2.79B Latest reported FY

About Biogen

Biogen is a global biotechnology company that has a particular focus on neuroscience. The company specializes in the discovery, development, and delivery of therapies for neurological disorders, such as multiple sclerosis and other complex and devastating diseases.

Founded in 1978, the company has a long history in the biotechnology industry. Its business model is centered on research and development, which leads to the commercialization of new drugs. This, in turn, generates value for shareholders and the communities it serves.

MoreLess Source: Dealroom company data

At a glance

Status: Listed
Founded: 1978
Headquarters: Cambridge, United States
Listing: IPO 1991
Employees: 7,849
Open positions: 169
Dealroom signal: 68.4/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Intellectual Property, Risk Management, Biotechnology, Oncology, DNA, Neurology, Genetics and genomics, Autoimmune, Genome Engineering
Technology: Deep Tech
Business model: Manufacturing
Client focus: b2b
Investment activity: 32 companies, latest Aug 2026
Capital deployed: $668M
Preferred round: ACQUISITION
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
GRANTOther financing	Apr 2018	$2.1M	—	Undisclosed	—
IPO✓Exit	Sep 1991	$0	—	Undisclosed	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin	R&D
2026	$10B	+5.6%	$2.8B	26.7%	$997M	9.5%	$1.8B
2025	$9.9B	+2.2%	$3.4B	34.4%	$1.3B	13.1%	$1.8B
2024	$9.7B	-1.6%	$3B	31.2%	$1.6B	16.9%	$2B
2023	$9.8B	-3.3%	$2.6B	26.4%			$2.5B
2022	$10B	-7.4%	$2.7B	26.4%
2021	$11B	-18.3%	$3.7B	33.3%
2020	$13B	—	$4.8B	35.8%

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Biogen website traffic

Latest recorded traffic for Biogen is 220K monthly website visits, up 22.2% over the last three months. Biogen's team declined 22.6% over the past year.

Latest monthly visits220K 3-month web change+22.2% 1-year team growth-22.6%

Monthly website visitsDec 2018–Oct 2020

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Senior Associate II, Quality AuditsUnited States, Cambridge, Binney St, 225 · Accounting · Oct 6, 2026 Engineer II/III, AutomationUnited States, Cambridge, Binney St, 225 · Other · Oct 6, 2026 Talent Sourcing PartnerUnited States, Cambridge, Binney St, 225 · Human Resources · Oct 6, 2026 Maintenance Planning & Scheduling Administrator IIIUnited States, Cambridge, Binney St, 225 · Project Management · Oct 6, 2026 Principal IT Analyst - Veeva RIMUnited States, Cambridge, Binney St, 225 · Business Intelligence · Oct 6, 2026 Associate Medical Director, Clinical Development, Rare Neurology (SMA)Cambridge, Massachusetts, United States, Northern America, Americas · Other · Oct 6, 2026 HEAL (Health Ecosystem Account Leader) | Market Access - Mercado Privado (São Paulo)São Paulo, Brazil, South America, Americas · Marketing & Communication · Oct 4, 2026 Responsable Senior Communication Aires Thérapeutiques & Engagement PatientsParis, France, Western Europe, Europe · Marketing & Communication · Oct 4, 2026

8 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ALAllelicaSoftware as a Service that allows clinical genetics lab to perform Polygenic Risk Score analysis	San Francisco, United States	Operational	11	$3.4M	$6.6M
HDHorizon DiscoveryGene editing and modulation tools for research	Cambridge, United Kingdom	Acquired
GEGeneAssessNew jersey-based biotechnology company working to validate fry, a cancer molecular signature gene	New Brunswick, United States	Operational
PTPear TherapeuticsPear discovers, develops, and commercializes Prescription Digital Therapeutics to treat diseases with high unmet need	Boston, United States	Closed
INInspirnaBiotechnology company developing drugs for the treatment of cancer	New York City, United States	Operational
TETevaGlobal Generic Pharmaceuticals Company	Petah Tikva, Israel	Operational
TOToxysProvides innovative in vitro toxicity screening solutions to rapidly identify hazardous and potential carcinogenic properties of novel compounds during the early phases of product and drug development	Leiden, Netherlands	Operational
RERepairogenRepairogen employs proprietary DNA-repair technologies to create advanced, scientifically-proven skincare products	New York City, United States	Operational